Seeking Alpha

Sharon di Stefano

 
View Sharon di Stefano's StockTalks BY TICKER:
  • Sharon di Stefano
    Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies $CVM http://seekingalpha.com/a/1fqr1
    Aug 12, 10:43 AM
    Reply (2)
    • Erbois: Thanks for the article, I just shorted $CVM! LOL! Just like I did with $ORMP
      Aug 12, 11:01 AM
    • FungibleFungi: lol dirty
      Mon, 7:56 PM
      • Sharon di Stefano
        Celsion's EGEN Acquisition Brings Immunotherapy And RNA Therapeutics To Its Cancer Platform $CLSN http://seekingalpha.com/a/1dxo9
        Jul 22, 1:29 PM
        Reply
          • Sharon di Stefano
            NIH's Human Placenta Project Is Validation For Placental Cells Curing Deadly Diseases $PSTI http://seekingalpha.com/a/1dh1d
            Jul 10, 9:58 AM
            Reply
              • Sharon di Stefano
                Can-Fite's Promising Psoriasis Drug Could Unseat Celgene's Latest Entrant $CANF http://seekingalpha.com/a/1cqc7
                Jun 17, 6:25 PM
                Reply
                  • Sharon di Stefano
                    The Importance Of Being Oral $ORMP http://seekingalpha.com/a/1c9al
                    Jun 3, 6:32 PM
                    Reply
                      • Sharon di Stefano
                        Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff $RNN http://seekingalpha.com/a/1a4mb
                        Apr 21, 4:23 PM
                        Reply
                          • Sharon di Stefano
                            Oramed Can Benefit As MannKind Opens The Diabetes Market For Novel Drugs $ORMP http://seekingalpha.com/a/19oft
                            Apr 8, 11:01 AM
                            Reply
                              • Sharon di Stefano
                                Cel-Sci Sees Rapid Enrollment For Phase III Head And Neck Cancer Trial $CVM http://seekingalpha.com/a/19hpv
                                Apr 2, 11:39 AM
                                Reply (1)
                                • piem18848: The problem with CVM has always been money. Do you foresee it still being a problem for them in the future? And if not how?
                                  Apr 2, 1:28 PM
                                  • Sharon di Stefano
                                    Pluristem's Plant Approval From The FDA Could Provide Pathway To New Drug Partners $PSTI http://seekingalpha.com/a/18ob9
                                    Mar 12, 2:26 PM
                                    Reply
                                      • Sharon di Stefano
                                        Fortune 500 Pharma Giant Looking For Innovation Collaborates With DS Healthcare $BAYRY, $JNJ, $MRK http://seekingalpha.com/p/1mv8b
                                        Mar 12, 1:17 AM
                                        Reply
                                          • Sharon di Stefano
                                            Pluristem's Preeclampsia Effort Pushes PLX Platform $PSTI http://seekingalpha.com/a/17xtx
                                            Feb 26, 10:29 AM
                                            Reply
                                              • Sharon di Stefano
                                                Celsion's Newest Cancer Treatment Adds To Upside $CLSN http://seekingalpha.com/a/17ax5
                                                Feb 13, 4:37 PM
                                                Reply
                                                  • Sharon di Stefano
                                                    Navy CRADA Fast Tracks Cel-Sci's Immunotherapy For HPV $CVM http://seekingalpha.com/a/16xqp
                                                    Feb 7, 6:19 AM
                                                    Reply
                                                      • Sharon di Stefano
                                                        Analysis Of Oramed's Positive Phase IIa Safety Data Makes Opportunity Obvious $ORMP http://seekingalpha.com/a/16qwb
                                                        Feb 5, 3:20 AM
                                                        Reply (1)
                                                        • BioInvestor2013: great post Sharon !! Adam Feuerstein is a Nerd
                                                          Feb 6, 9:19 AM
                                                          • Sharon di Stefano
                                                            Oramed's Data Will Define A New Standard For Diabetes $ORMP http://seekingalpha.com/a/169lj
                                                            Jan 28, 7:48 AM
                                                            Reply
                                                              • Sharon di Stefano
                                                                Mesoblast Is No Match For Pluristem's IP And Manufacturing $PSTI, $MBLTY http://seekingalpha.com/a/15rq7
                                                                Jan 16, 6:52 AM
                                                                Reply (2)
                                                                • petethepanzer: where does athersys fit in with these two
                                                                  Jan 19, 2:01 PM
                                                                • bababoubou: $MBLTY hi sharon who are the main shareolders???privat??
                                                                  Jan 28, 8:32 AM
                                                                  • Sharon di Stefano
                                                                    DS Healthcare's New IND Should Boost Its Valuation In Line With Specialty Pharma $DSKX http://seekingalpha.com/a/15o0b
                                                                    Jan 14, 8:30 AM
                                                                    Reply
                                                                      • Sharon di Stefano
                                                                        Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial $RNN http://seekingalpha.com/a/15im5
                                                                        Jan 9, 12:20 PM
                                                                        Reply (4)
                                                                      • View all 4 replies
                                                                        • subrkaus3: thanks! this one is a keeper for long term! right now there is high speculation so price will fluctuate wildly! GL!
                                                                          Jan 13, 7:20 PM
                                                                        • GrowthGeek: Agreed, I think it will zig zag for a while between 1.10 and 1.70 and then make its next move. Should easily be 2.5 or above by year end.
                                                                          Jan 14, 5:50 PM
                                                                          • Sharon di Stefano
                                                                            Pluristem's Positive Data Could Open Massive Muscle Injury Market $PSTI http://seekingalpha.com/a/15e4h
                                                                            Jan 6, 7:17 PM
                                                                            Reply